Denali Therapeutics Inc.
DNLI
Positions held
Your positionsDNLI isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Denali Therapeutics Inc. is focused on innovative therapies for neurodegenerative diseases, positioning itself in a niche market with significant unmet needs.
- The company has a strong recommendation of 'strong_buy' from analysts, indicating positive sentiment among investors.
- Denali's market cap stands at approximately $3.08 billion, reflecting its potential for growth in the biotechnology sector.
- Denali Therapeutics has reported a negative operating margin of -36.01%, indicating challenges in managing operational costs.
- The company has consistently posted net losses, with a net income of -145.224 million in 2023 and -512.54 million in 2025.
- Currently, Denali has a score of 'Strong Sell' with a score of -23.00, suggesting bearish sentiment among market analysts.
Fundamentals
| Market cap | $2.98B | Enterprise value | $2.31B | Trailing P/E | — | Forward P/E | -7.72 |
| PEG | — | Price / book | 3.57 | Beta | 1.02 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -36.0% |
| Profit margin | 0.0% | ROE | -54.9% | ROA | -29.1% | Debt / equity | 0.05 |
| Current ratio | 8.37 | Free cash flow | -$268.53M | Analyst recommendation | strong_buy | Mean target | $36.06 |
| 52w high | $27.30 | 52w low | $13.75 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -3622.1% | — | — | — | — | — |
| Net income | -$128M | -$128M | -$129M | -$127M | -$124M | — |
| Gross margin | 97.4% | — | — | — | — | — |
| Gross profit | $3.5M | — | — | — | $0.0M | — |
| Operating income | -$131M | -$137M | -$137M | -$137M | -$135M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $331M | $108M | — |
| Op margin | — | — | -59.5% | -314.2% | — |
| Net income | -$513M | -$423M | -$145M | -$326M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$555M | -$502M | -$197M | -$341M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?
2026-09-04 · Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing
2026-08-25 · B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating
2026-08-20 · DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
2026-08-20 · Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
2026-08-13 · Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
2026-08-07 · DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
2026-08-07 · UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating
2026-08-07 · Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-07 · Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
2026-08-07 · Denali Therapeutics Q2 Earnings Call Highlights
2026-08-06 · Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns